# Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

> **NCT03182907** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 148 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **BIOLOGICAL:** Bezlotoxumab
- **DRUG:** Placebo
- **DRUG:** Antibacterial drug treatment (ABD)

## Key facts

- **NCT ID:** NCT03182907
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-27
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-05-12
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03182907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03182907, "Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03182907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*